Introduction
Acetazolamide has for several years been known to reduce the symptoms of acute mountain sickness, i.e. the cerebral symptoms that many sea-level dwellers experience during the first days or weeks of exposure to high altitude hypoxia.'4 The drug increases ventilation5'6 and also causes a considerable increase in cerebral blood flow (CBF) a few minutes after intravenous injection of the drug.7'9 Both factors might be of importance for the beneficial effect as both changes would, other factors being equal, tend to augment cerebral oxygen supply. Which one of these two factors is the most important under the conditions of many days of oral acetazolamide taken by mountaineers during acclimatization after abrupt ascent to altitude?
The present study reports sea-level (normoxic) studies of alveolar Pco2 and CBF during 10 days of oral acetazolamide administration to normal volunteers. This is a baseline study for similar observations at hypoxia.
The intravenous injection of 1 g of acetazolamide results in a prompt increase in CBF.7 CBF measured in conscious human subjects at sea level increased by about 50% above control values 3 minutes after injection. There was a further rise to about 60% of the control value after 20 minutes. The cerebral oxygen uptake was not affected. This is important, as it uptake was not affected. This is important, as it permits the calculation of blood flow as the percentage rise in the reciprocal cerebral arterio-venous oxygen difference. 7 The duration of this response is not known, but in view of the fairly rapid elimination of acetazolamide, complete inhibition of carbonic anhydrase cannot be expected to last for long. It is interesting to note, in contrast, that the intravenous injection of 500 mg of acetazolamide increases CBF only insignificantly during the first 5 minutes8 with a rise of 30% being seen later.9 This suggests that in order to obtain a sustained increase of CBF, a high dose of oral acetazolamide would be required.
Methods and results
Preliminary studies with oral administration are now being performed in our laboratory. Cerebral blood flow has been measured in 8 normal subjects in normoxia at sea level by the intravenous xenon-133 injection method.'"'" This study showed that a single oral dose of 1 g of acetazolamide increased CBF (40-50%) at 3 hours with only a small decrease in endexpiratory Pco2. The following 10 days, 500 mg acetazolamide was taken twice daily. After 2 days CBF had practically normalized but clear cut hyperventilation was evident with alveolar Pco2 reaching 70% of normal at 10 days (Figure 1 Despite reservations on extrapolating to hypoxic conditions the present study suggests that carbonic anhydrase inhibitors should be commenced several days before abrupt ascent to altitude; that it should be continued throughout the stay and that a compound and dose should be used which inhibits the anhydrase in both erythrocytes and brain cells. Much further work should be carried out to clarify these and other points. The techniques described are atraumatic and could be used in the field. It is important as high mountain climbing and trekking has become so popular; why mar the pleasure with unnecessary discomfort and risk!
